Express Pharma

SEPTEMBER 30, 2024

The site specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products. Upon completion of the expansion, scheduled for Q1 2027, this will increase to over 240 annual batches. Current capacity at the Lexington site stands at 104 product batches per year.

Sterile Compounds 97

Sterile Compounds Compounding 97

Express Pharma

SEPTEMBER 24, 2023

billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). CYB-003, a small-molecule drug that is indicated for major depressive disorder, is expected to launch in the US in December 2027 and is forecast to generate $1.4 It is expected to launch in the US in 2027 and in the EU in 2028 and generate $0.9

Drug Development 52

Drug Development Compounding 52

European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.

Labelling 98

Labelling Compounding 98

pharmaphorum

FEBRUARY 2, 2022

ViiV claimed the latter compound infringes its patents for dolutegravir and other compounds based on the drug’s chemical scaffold. The dispute centred around Gilead’s triple-drug regimen Biktarvy , which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir.

Compounding 72

Compounding 72

pharmaphorum

FEBRUARY 3, 2022

As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9%

Compounding 52

Compounding Packaging Biosimilars Vaccines 52

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

Compounding 59

Compounding Labelling 59

pharmaphorum

JANUARY 27, 2023

An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Diabetes 64

Diabetes Compounding Dosage Communication 64

Quality Matters

MARCH 1, 2024

USP has a long-standing history of healthcare standards including those for compounding preparations that are tailored to meet the unique needs of patients who may not otherwise have access to their medications. DTx is projected to have a cumulative annual growth rate of up to 25.4% in the U.S.

Labelling 52

Labelling Compounding 52

pharmaphorum

JANUARY 16, 2023

Ageing will only compound the challenge: high income country populations are already old, but between 2015 and 2050, the proportion of the world’s population aged over 60 will nearly double, from 12% to 22%, and, by 2050, 80% of older people will be living in low- and middle-income countries. Innovation will power the market.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies Compounding Vaccines 95

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 percent through 2027. The market for biologics The growing interest in biologics resonates with their impressive expansion on the global market.

Vaccines 98

Vaccines Immunity Immunization Compounding 98

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9 billion in sales in 2019, increasing to $136.2

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmaceutical Technology

APRIL 24, 2023

Meanwhile, the Indian biologics market is expected to grow to $12 billion by 2025, with a compound annual growth rate (CAGR) of 22%. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027.

Vaccines 52

Vaccines Compounding Communication Immunity 52

Pharmaceutical Technology

JUNE 21, 2023

Dr. Doug Cole, co-founder of Empress Therapeutics, explained that Chemilogics links gene pathways to small molecule compounds, allowing for drugs with the versatility of small molecules without the unpredictable, expensive, and time-consuming discovery process. Murray KcKinnon, PhD He joined Empress as chief scientific officer.

Compounding 52

Compounding Communication Immunity Immunization 52

FDA Law Blog: Biosimilars

FEBRUARY 11, 2024

Few would oppose FDA-approved marijuana-derived medications if marijuana compounds are found to have medical value; the National Institute of Health should continue to fund research on any potential medical value of marijuana and on the harms of highly potent products.

Controlled Substances 57

Controlled Substances Chemotherapy Compounding 57